Regenerative medicine company Mesoblast Limited has announced that it has been granted three key new patents by the United States Patent and Trade Mark Office (USPTO) and the State Intellectual Property Office of the People’s Republic of China.
These patents deliver major commercial advantages and offer long term protection in these territories for the company’s products based on its proprietary Mesenchymal Precursor Cell (MPC) adult stem cell technology platform.
In the United States, USPTO patent 8,367,405 confers Mesoblast with exclusive rights through to March 2029 to compositions-of-matter covering its current products.
This patent extends by more than seven years Mesoblast's exclusive commercial rights in the United States, the world’s largest healthcare market, to MPC compositions-of-matter beyond those rights already conferred by USPTO patents 7,122,178 and 8,158,118 whose expiry had previously been extended to November 2021.
In China, patents CN200580040212.1 and CN200580039970.1 provide Mesoblast with exclusive MPC product commercial rights and protection through to 2025.
These patents provide Mesoblast with long-term composition-of-matter protection for the company's MPC products derived from an unlimited range of tissue sources, such as bone marrow, adipose tissue, placenta, umbilical cord, and dental pulp.
These Chinese patents underpin Mesoblast's corporate strategy to target the world’s largest emerging market for regenerative medicines, and to protect its manufacturing processes and know-how.